Hepatitis B Topics HBV Treatment
AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 December 2017 00:00
- Written by Liz Highleyman
JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 15 December 2017 00:00
- Written by Liz Highleyman
ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the infection, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA, and antigens, and potency was enhanced when followed by tenofovir, according to early results from the ACHIEVE trial presented at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
Web Design and Development by